Wesana Health announces its inclusion in AdvisorShares

CHICAGO and TORONTO, October 01, 2021 (GLOBE NEWSWIRE) – Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), an emerging data-driven life sciences company focused on developing innovative approaches to better understand, protect and improve neurological health and performance, including through the advancement of psychedelic drugs, is pleased to announce announce its inclusion in the ETF AdvisorShares Psychedelics (the “Fund”). , which currently trades under the ticker symbol “PSIL” on the NYSE Arca Exchange.

The recently launched fund primarily focuses its strategy on investing in publicly traded companies in the life sciences, biotechnology and pharmaceuticals sectors that derive at least 50% of their net income or devote 50% of their active in the advancement of psychedelic compounds. The Fund seeks to highlight leaders in the psychedelics industry as their main holdings.

Chad Bronstein, Executive Chairman of Wesana, said: “We are extremely pleased to have been selected as a core component of the new AdvisorShares Psychedelics ETF. Inclusion in this ETF is further validation of Wesana’s evolution as a publicly traded company and the impact Wesana’s major initiatives have had on the psychedelics industry. By strengthening our shareholder base and improving our visibility in the global investment community, we are excited about the next steps in bringing Wesana’s unique approach to neurological health and wellness to patients across the country.

You can find additional information about the ETF AdvisorShares Psychedelics here.

About Wesana Health
Wesana Health is an emerging life sciences company championing the development of innovative approaches to better understand, protect and improve neurological health and performance. Through extensive clinical research and academic partnerships, Wesana Health develops evidence-based formulations and protocols, including psilocybin-based therapies, that empower patients to overcome neurological, psychological and mental health disorders. Learn more at www.wesanahealth.com.

Forward-looking information and statements

This press release contains “forward-looking information” within the meaning of securities laws applicable to the Company, including, but not limited to: information regarding the completion and timing of the completion of the issuance of securities. DRS statements to former PsyTech shareholders, expectations for the effects of the proposed Transaction, including the potential expansion of the Company’s clinical platform upon completion of the Transaction, expectations regarding the markets that the Company must conclude following completion of the Transaction, the Company’s ability to successfully achieve its business objectives following completion of the Transaction, expectations regarding the method by which future income is generated, and any other statements that can predict, predict, indicate or imply future plans, intentions, activity levels, results, financial position, performance or achievements operational or financial. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is planned”, “budget”, “planned”, “estimates”, “forecasts”. “,” Hears “,” anticipates “, goes”, “projects” or “believes” or variations (including negative variations) of these words and expressions, or statements that certain actions, events, results or conditions “may “,” Could “,” would “,” could “or” will “will be taken, will occur or will be carried out. With the exception of statements of historical fact, the information contained in this document constitutes forward-looking information.

Forward-looking information is not a guarantee of future performance and is based on a number of estimates and assumptions made by management at the date the statements are made, including, among others, assumptions about: development costs remaining consistent with budgets; favorable equity and debt capital markets; the ability to raise sufficient capital to advance the business of the Company; favorable operating conditions; political and regulatory stability; obtain and maintain all required licenses and permits; receiving government approvals and permits; lasting stability of the workforce; stability of capital goods markets; the level of demand for the Company’s products and services; the Company’s ability to succeed in its research and development initiatives; and the availability of third party service providers and other inputs for the Company’s operations. While the Company considers these assumptions to be reasonable, they are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could result in performance. , achievements, actions, events, results or conditions are materially different from those projected in the forward-looking information. Many assumptions are based on factors and events beyond the control of the Company and there can be no assurance that they will prove to be correct.

In addition, such forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the Company’s plans, intentions, activities, results, financial position, performance or actual achievements to be materially different from any plan, intention, activities, results, financial situation, performances or achievements expressed or implied by this forward-looking information. Such factors include, among others: the research and development of drugs targeting the central nervous system (“CNS”) being particularly difficult; failure to comply with health and data protection laws and regulations; delays in clinical trials resulting in delays in commercialization; the inability to file applications for new investigational drugs to begin clinical trials in a timely manner; difficulty in recruiting patients for clinical trials; competition from other biotechnology and pharmaceutical companies; violations of laws and regulations resulting in repercussions; psychedelically inspired drugs may never have been approved as drugs; regulatory or policy change; maintain and improve the reputation and recognition of the brand; the use of third parties to plan, conduct and monitor preclinical studies and clinical trials; market scale and supply requirements for quality manufactured drugs; negative results of clinical trials or studies of others; negative operating cash flow and going concern; the negative impact of future losses and negative cash flows from operations; additional capital requirements; lack of income produced; advertising or unfavorable consumer perception; fail to meet publicly announced milestones; drawing on the skills and experience of key leaders and scientists; disruptions due to acquisitions or collaborations; risk of product liability claims; Covid-19[FEMALE;litigation;lesconflitsd’intérêts;historiqued’exploitationlimité;expositionàlafluctuationdestauxdechange;theexécutiondesjugementsetlasignificationdesactesdeprocédureauxadministrateursetdirigeants;capacitéàprotégerlapropriétéintellectuelle;changementsdansledroitdesbrevets;lesexigencesdepartagedelapropriétéintellectuelleaveclesfournisseursdeservices;conjonctureéconomiquegénéraledumarchéetdesaffairesd’autresfacteursderisqueycomprisceuxfigurantdanslanoticeannuelledelaSociétédatéedu3septembre2021déposéesurleprofildelaSociétésurSEDARàl’adressewwwsedarcometdiscutésdanslesautresdocumentspublicsdelaSociétédisponiblessurSEDARBienquelaSociétéaittentéd’identifierdesfacteursimportantsquipourraiententraînerdesécartsimportantsentrelesrésultatsréelsd’autresfacteurspeuventfaireensortequelesrésultatsnesoientpasceuxanticipésestimésouprévusRiennegarantitquecesinformationsprospectivesserévélerontexactescarlesrésultatsréelsetlesévénementsfuturspourraientdifférersensiblementdeceuxanticipésdansthisinformationthereforereadersshouldtakeunduerelianceontheforward-lookinginformation[FEMININE;litige;lesconflitsd’intérêts;historiqued’exploitationlimité;expositionàlafluctuationdestauxdechange;l’exécutiondesjugementsetlasignificationdesactesdeprocédureauxadministrateursetdirigeants ;capacitéàprotégerlapropriétéintellectuelle;changementsdansledroitdesbrevets;lesexigencesdepartagedelapropriétéintellectuelleaveclesfournisseursdeservices ;conjonctureéconomiquegénéraledumarchéetdesaffairesd’autresfacteursderisqueycomprisceuxfigurantdanslanoticeannuelledelaSociétédatéedu3septembre2021déposéesurleprofildelaSociétésurSEDARàl’adressewwwsedarcometdiscutésdanslesautresdocumentspublicsdelaSociétédisponiblessurSEDARBienquelaSociétéaittentéd’identifierdesfacteursimportantsquipourraiententraînerdesécartsimportantsentrelesrésultatsréelsd’autresfacteurspeuventfaireensortequelesrésultatsnesoientpasceuxanticipésestimésouprévusRiennegarantitquecesinformationsprospectivesserévélerontexactescarlesrésultatsréelsetlesévénementsfuturspourraientdifférersensiblementdeceuxanticipésdanscesinformationsParconséquentleslecteursnedevraientpassefierindûmentauxinformationsprospectivesLesinformationsprospectivessontfourniesetfaitesàladatedececommuniquédepresseetlaSociéténes’engageàaucuneobligationderéviseroudemettreàjourtouteinformationprospectiveautrequecellerequiseparlaloiapplicable

For more information please contact:

Investor contact:
Keenan Gentry
Email: [email protected]
Telephone: 773-236-7972

Media contacts:
Nick Opich / Fallon Carter
KCSA strategic communication
Email: [email protected]
Telephone: 212-896-1206

On behalf of the Board of Directors:
Daniel Carcillo, President and CEO
Telephone: (773) 236-7972

About Meredith Campagna

Check Also

Institutional Investors Sell $5.3 Billion Worth of BTC Since Luna Debacle

Many have speculated that the fallout from the Terra blockchain, its native token, and its …